Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma

<div>Cell viability following single-agent defactinib and dasatinib treatment in DSRCT, ES, ARMS, and ERMS cell lines. Cell viability (%) following single-agent defactinib and dasatinib treatment in the JN-DSRCT-1, TC32, Rh30, and RD cell lines. The dotted line represents the IC50 value.</div>

Sarcoma

fig3

Figure 3

Figure 3: Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma 